(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...
Patients exposed to a higher dose may be subject to bleeding complications. Apotex Corp announced the voluntary recall of 2 batches of Enoxaparin Sodium Injection ...
The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...
Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion ...
The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: orthopedic surgery of the hip or knee; high-risk abdominal, gynecological, or urological surgeries; ...
Princeton, New Jersey, April 25, 2012 – Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi's Lovenox® Injection Multiple-Dose Vials, in ...
WESTON, Fla., Feb. 2, 2021 /CNW/ - Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP to consumer level due to a packaging error ...
July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback